Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.56 |
| ▸ | NPY1R | P25929 | 9/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117539 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117541 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31252942 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29464056 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30309304 | 0.94 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30418999 | 0.93 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30475880 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30589456 | 0.91 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30592738 | 0.91 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29461983 | 0.91 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | HAGH, OAT, NLN | NPY4R 886/4885NPY1R 743/4885NPY5R 1380/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPY4R 4783/4885NPY1R 4818/4885NPY5R 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.